GULF PHARMACEUTICAL INDUSTRIES |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.968 AED | +2.87% |
|
+1.89% | +25.88% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Most analysts recommend that the stock should be sold or reduced.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +26.66% | 296M | C+ | ||
| +3.37% | 69.25B | A | ||
| +12.55% | 9B | A- | ||
| -12.75% | 4.96B | A- | ||
| +42.38% | 4.47B | - | ||
| +5.23% | 3.9B | B- | ||
| +21.69% | 2.45B | B | ||
| -19.05% | 2.41B | C- | ||
| -28.72% | 2.23B | - | ||
| +11.13% | 2.02B | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- JULPHAR Stock
- Ratings Gulf Pharmaceutical Industries
